Search - tctmd.com

Displaying 561 - 580 of 864

Sort: Relevancy | Date

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Caitlin E. Cox

October 02, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Todd Neale

September 18, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Statins Started in Kids With FH Provide Benefits in Adulthood

Recurrent Events Common Among Young Patients With CAD

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

TCTMD’s Top 10 Most Popular Stories for September 2019

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content